发明授权
US08802374B2 Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
有权
截短的背景生长因子受体(EGFRt)用于转导的T细胞选择
- 专利标题: Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection
- 专利标题(中): 截短的背景生长因子受体(EGFRt)用于转导的T细胞选择
-
申请号: US13463247申请日: 2012-05-03
-
公开(公告)号: US08802374B2公开(公告)日: 2014-08-12
- 发明人: Michael C. Jensen
- 申请人: Michael C. Jensen
- 申请人地址: US CA Duarte
- 专利权人: City of Hope
- 当前专利权人: City of Hope
- 当前专利权人地址: US CA Duarte
- 代理机构: Perkins Coie LLP
- 代理商 Lauren Sliger
- 主分类号: C12Q1/68
- IPC分类号: C12Q1/68 ; C07K14/00
摘要:
A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.
公开/授权文献
信息查询